natgillin/translations-raw huggingface dataset:
Use according to claim 14, characterized in that the fibre product (2, 2.1, 2.2, 2.3) comprises at least one first fibre layer at least partially interspersed with the filter material (6) for binding mineral oils, for reducing the migration of mineral oil substances from the fibre product (2, 2.1, 2.2, 2.3) into another product to a migration value of at least less than 0.6 mg/kg. 
Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je u vlaknastom proizvodu (2, 2.1, 2.2, 2.3) razasut filtarski materijal (6) za vezanje tvari mineralnog ulja radi smanjivanja migriranja tvari mineralnog ulja iz vlaknastog proizvoda (2, 2.1, 2.2, 2.3) u drugi proizvod do vrijednosti migriranja od najmanje manje od 0,1 mg/kg.
which process comprises reaction of a compound of formula II, wherein R1 and R3a, R3b, R3c, R3d and R3e are as defined above, with a compound of formula III, 
koji postupak sadrži reakciju spoja formule II, [image] gdje R1 i R3a, R3b, R3c, R3d i R30 su kao gore definirani, sa spojem formule III, [image] gdje X i R2a, R2b, R2c, R2di R2e su kao gore definirani.
In embodiments, the methods involve expressing a protein having an amino acid motif that can be recognized by an isoprenoid transferase. 
(a) ekspresiju protutijela vezanog za aminokiselinski motiv koji se može prepoznati izoprenoid transferazom;
A compound for use according to claim 1, wherein said cells are associated with a hematological cancer. 
Tvar za uporabu u skladu s patentnim zahtjevom 1, pri čemu su navedene stanice povezane s hematološkim malignitetima.
The dressing (10) of claim 1, wherein a minimum thickness of the combination of the substrate (12) and the adhesive layer (18) is about 8 µm. 
Zavoj (10) sukladno patentnom zahtjevu 1, naznačen time, da je minimalna debljina kombinacije supstrata (12) i ljepljivog sloja (18) oko 8 um.
The pharmaceutical composition of claim 5, wherein the polypeptide is coupled to an immunogenic carrier selected from the group consisting of keyhole limpet haemocyanin, bovine serum albumin, ovalbumin and fowl immunoglobulin. 
Farmaceutska kompozicija u skladu sa patentnim zahtjevom 13, gdje dodatna supstanca je odabrana iz grupe koja se sastoji od: masti, šećera, šećernog lanca, acetil grupe, prirodnog polimera i sintetičkog polimera.
The procedure comprises a suitable method for the covalent conjugation of the hrEGF to the carrier protein P64K, and the purification of this conjugated by using ultra filtration membranes in a range of 50-100 kDa, to remove the biologically inactive species conjugated (without immunogenic activity), as well as other chemical impurities. DETAILED DESCRIPTION OF THE INVENTION 
Postupak dobivanja sastava cjepiva prema zahtjevu 1, po zdravstvenim standardima, naznačen time, da spomenuti postupak obuhvaća prikladne uvjete za kovalentnu konjugaciju EGF-a na nosač proteina rP64K i purifikaciju molekularnog kompleksa, uporabom ultrafiltracijske membrane, za odstranjivanje biološki neaktivnih konjugiranih vrsta i ostalih kemijskih nečistoća.
A method of attenuating expression of a target gene in a mammalian cell, the method comprising introducing into the mammalian cell an expression vector comprising a sequence encoding a pre-miR-451 structural mimic which is DICER independent and requires AGO2 catalysis and which consists of a short hairpin RNA molecule (shRNA) operably linked to an RNA polymerase promoter, the shRNA comprising: a first sequence of 21, 22 or 23 nucleotides fully complementary to a sequence in the coding region of the target gene, 
Postupak in vitro sniženja ekspresije ciljnog gena u stanici sisavca, naznačen time, da postupak obuhvaća ubacivanje u stanicu sisavca ekspresijskog vektora, koji sadrži slijed koji kodira molekulu kratke RNA-ukosnice, prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu je molekula shRNA eksprimirana u stanici sisavca u količini dovoljnoj da snizi ekspresiju ciljnog gena zahvaljujući specifičnosti slijeda nukleotida, čime je inhibirana ekspresija ciljnog gena.
Compounds according to claim 1 wherein: represents wherein R8 and R8' are as defined in claim 1. 
[image] predstavlja [image] pri čemu su R8 i R8' kako je definirano u patentnom zahtjevu 1.
n is at each occurrence independently selected from 0–3; and/or pharmaceutically-acceptable salts, prodrugs, solvates, stereoisomer, and/or hydrates thereof. 
N(CHs),, imidazolil, iili N-morfolinil; i/ili farmaceutski prihvatljive soli, solvati, stereoizomeri i/ili hidrati ovog spoja.
This gave a heavy precipitation which was removed by filtration. 
Uslijed toga dolazi do nastanka čvrstog taloga koji se uklanja filtracijom.
The curves were normalised by assuming the lowest value of INF-Y equal to 0% and the highest value of INF-Y equal to 100%, respectively. 
Krivulje su bile normalizirane pretpostavljajući da je najniža vrijednost INF-y jednaka 0%, a najviša vrijednost INF-7 jednaka 100%.
wherein n is an integer and X− is an inorganic or organic pharmaceutically acceptable anion, such as halide, phosphate, phosphite, carbonate, bicarbonate, sulphate, bisulfate, hydroxide, nitrate, persulfate, sulfite, sulphide, acetate, ascorbate, benzoate, citrate, dihydrogen citrate, hydrogen citrate, oxalate, succinate, tartrate, taurocholate, glycocholate, colate. 
(ll) naznačen time da n je cijeli broj i X je anorganski ili organski farmaceutski prihvatljiv anion, kao halid, fosfat, fosfit, karbonat, bikarbonat, sulfat, bisulfat, hidroksid, nitrat, persulfat, sulfit, sulfid, acetat, askorbat, benzoat, citrat, dihidrogen citrat, hidrogen citrat, oksalat, sukcinat, tartrat, taurokolat, glikokolat, ili kolat; koji postupak sadrži: reakciju alilamina u prisutnosti kiseline sa sredstvom za umrežavanje prema formuli (TV)
A compound or pharmaceutically acceptable salt thereof, according to claim 1, wherein the compound is 9-cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one. 
Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, naznačen time što je spoj 9-ciklopropiletinil-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidropirimido[6,1-a]izokinolin-4-on.
In yet another aspect of the invention is a method of treatment of inflammatory diseases, disorders and conditions characterized by or associated by excessive unregulated production of cytokines or Inflamatory mediators which comprises administering to a subject a therapeutically effective amount of a compound of the invention. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3 u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time što je ili jo povezana s prekomjernom nereguliranom proizvodnjom citokina ili posrednika upale.
Alternatively such a base is, for example, an alkali metal hydride, for example sodium hydride, an alkali metal or alkaline earth metal amide, for example sodium amide or sodium bis(trimethylsilyl)amide, or a sufficiently basic alkali metal halide, for example cesium fluoride or sodium iodide. 
Alternativno, takva baza je na primjer, hidrid alkalijskog metala, npr. natrij-hidrid, metalni amid alkalijskog ili zemno-alkalijskog metala npr. natrijamid ili natrij bis(trimetilsililjamid, ili dovoljno bazičan halid alkalijskog metala, na primjer cezij-fluorid ili natrij-jodid.
A pharmaceutical composition according to claim 6, wherein the coating agent is one or more species selected from among hypromellose, ethyl cellulose, and polyvinyl alcohol. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je sredstvo za oblaganje jedna ili više vrsta koje se bira iz skupine koju čine hipromeloza, etilceluloza, te polivinil-alkohol.
Use according to claims 1 to 4 wherein the composition is up to 83% protective in a population of vaccinated individuals against severe gastro-enteritis caused by infection of rotaviruses of at least two non-G1 serotypes. 
Upotreba u skladu s patentnim zahtjevima 1 do 4, naznačena time što pripravak štiti do 83% u populaciji osoba cijepljenih protiv jakog gastroenteritisa uzrokovanog infekcijom od strane najmanje dva serotipa rotavirusa koji nisu G1.
Soft gelatin capsules may be prepared with capsules containing the active compound of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatin capsules. 
Kapsule od mekane želatine mogu biti priređene s kapsulama koje sadrže aktivni sastojak iz ovoga izuma, biljno ulje, masnoću ili neki drugi pogodni prijenosnik za kapsule od mekane želatine.
The use of a compound of any one of embodiments 1 to 11, or a pharmaceutically acceptable acid addition salt thereof, for the manufacture of a medicament for the treatment of restless legs syndrome (RLS) or periodic limb movement disorder (PLMD) in a mammal. The use of a compound of any one of embodiments 1 to 11, or a pharmaceutically acceptable acid addition salt thereof, for the manufacture of a medicament for the treatment of movement disorders, poverty of movement, dyskinetic disorders, gait disorders or intention tremor in a mammal. 
Tvar iz patentnog zahtjeva 1 ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline za uporabu u liječenju psihoze, impotencije, zatajenja bubrega, zatajenja srca, hipertenzije, kognitivnog oštećenja, sindroma nemirnih nogu (RLS), periodičnog poremećaja pokreta udova (PLMD), poremećaja pokreta, oskudnosti pokreta, diskinetičkih poremećaja, poremećaja hoda, ili intencijskog tremora u sisavaca.
reacting the compound of formula VI with the compound of formula VII W—CH2-A2-R15 (VII) 
0" "o-z B) reakciji spoja formule VI s spojem formule VII
Following drying, lozenges are bolted from the starch moulds, and starch is removed from the surface of the lozenges using air jets or brushes. 
Poslije sušenja, tablete su odvojene iz škrobnih kalupa, i škrob se uklanja sa površine tableta primjenom zračnih mlaznica ili četkica.
is hydrogen or halo; provided that at least one of -R2 and R3 is hydrogen; 
R* je vodik ili halogen; uz uvjet da najmanje jedan od R? i R? je vodik;
The drippable ophthalmic gel according to claims 1 or 2, characterized in that the amount of povidone is in the range of > 0.8 % to 10 % by weight, preferably > 2.5 % to 10 % by weight. 
Bimatoprost oftalmološki gel u obliku kapi temeljem zahtjeva 1 ili 2, naznačen time da je količina povidona u rasponu od > 0,8 % do 10 % masenog udjela, poželjno > 2,5 % do 10 % masenog udjela.
Preparation of the title compound A mixture of the compound prepared in Example 1a above (2.4 g, 6.98 mmol), iron powder (1.16 g, 20.8 mmol) and glacial acetic acid (70 mL) is stirred at 50°C for 2.5 hours. 
Smjesu spoja proizvedenog u gornjem primjeru la (2,4 g, 6,98 mmolova), željeznog praha (1,16 g, 20,8 mmolova) i ledene octene kiseline (70 ml) miješa 2,5 sata pri 50%C. Reakcijsku smjesu se pusti ohladiti na sobnu temperaturu i zatim se ispari u vakuumu do suhog.
The use of oligofructose in the sugar replacement composition without wheat fibres may result in a too dark crust and crumb of the baked products. 
Uporaba oligofruktoze u sastavinama koje zamjenjuju šećer bez dodatka pšeničnih vlakana, mogla bi rezultirati dobivanjem previše tamne kore i unutrašnjosti pečenog proizvoda.
Next, the sidechain is cleaved to form the compound of Formula 24 (where R7═CH3; R8═H; R9═PhOMe in generalized formula R of Scheme 7), as exemplified in FIG. 29 . 
Nakon toga se bočni lanac odcijepi od spoja formule 24 (R;=CH; i Rz =H; Re=PhOMe u općoj formuli R iz sheme 7), kao stoje prikazano kao primjer na slici 29.
A process for producing a pharmaceutical composition according to any one of embodiments 26 to 29, said process comprising admixing said polypeptide or polynucleotide sequence or host cell with a pharmaceutically acceptable excipient, carrier or diluent; optionally said polypeptide or polynucleotide sequence or host cell is encapsulated in said process; wherein said polypeptide has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof; and wherein said polynucleotide sequence encodes a polypeptide which has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof and/or wherein said polynucleotide sequence has at least 75% identity to SEQ ID NO 1, SEQ ID NO 3 or SEQ ID NO 5 or variants, homologues, fragments or derivatives thereof. 
Postupak za proizvodnju farmaceutskog pripravka prema bilo kojem od zahtjeva 8 do 11, te navedeni postupak sadrži miješanje navedenog polipeptida ili polinukleotidne sekvence s farmaceutski prihvatljivim pomoćnim sredstvom, nosačem ili razrjeđivačem; proizvoljno navedeni polipeptid ili polinukleotidna sekvenca je inkapsulirana u navedenom postupku; pri čemu je navedeni polipeptid najmanje 75% identičan sa SEQ ID NO 2, SEQ ID NO 4 ili SEQ ID NO 6 i pri čemu navedena polinukleotidna sekvenca kodira navedeni polipeptid koji je najmanje 75% identičan sa SEQ ID NO 2, SEQ ID NO 4 ili SEQ ID NO 6 i/ili pri čemu navedena polinukleotidna sekvenca je najmanje 75% identična sa SEQ ID NO 1, SEQ ID NO 3 ili SEQ ID NO 5.
generating, with the camera, an electronic image of at least a portion of the form; 
dobivanja, kamerom, elektronske slike u najmanju ruku dijela formulara (400, 700);
The use of a compound according to any one of claims 1 to 16 for the preparation of a medicament for the treatment or prophylaxis of pain, atherosclerosis, regulation of bone mass, inflammation, ischemia, reperfusion injury, systemic fibrosis, liver fibrosis, lung fibrosis, kidney fibrosis, chronic allograft nephropathy, congestive heart failure, myocardial infarction, systemic sclerosis, glomerulonephropathy, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors. 
5. = Spoj prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time, da se upotrebljava u liječenju ili prevenciji boli, kod ateroskleroze, regulacije koštane mase, upala, ishemije, reperfuzijskih ozljeda, sistemske fibroze, jetrene fibroze, fibroze pluća, fibroze bubrega, kronične nefropatije bubrežnog presatka, kongestivnog zatajenja srca, infarkta miokarda, sistemske skleroze, glomerulonefropatije, toplinskih ozljeda, opeklina, hipertrofičnih ožiljaka, keloida, febrilnog gingivitisa, ciroze jetre ili tumora.
Water was added (50mL) and extraction was performed with MTBE (50mL x 3). 
Doda se voda (50 mL) i izvede ekstrakcija pomoću MTBE (3x50 mL).
Underground tank (tunnel-tank) in the open (sunken or above-ground) according to claim 1, wherein the metallic storage structure is characterized by the double element of hydraulic sealing extended to all the welded joints pratically constituting the double skin for the storage of the liquids. 
Spremnik u skladu s patentnim zahtjevom 1 s metalnom konstrukcijom za pohranu (2), naznačen time, da sadrži dvostruki element za hidrauličko brtvljenje (5) koji je proširen na sve zavare te u praktičnom smislu tvori dvostruku oplatu za pohranu tekućina.
The process according to any of claims 1 to 25, characterised in that the C8 to C24 aliphatic carboxylic acid(s) employed in step (b) are linear aliphatic carboxylic acids. 
Postupak prema bilo kojem od zahtjeva 1 do 15, naznačen time da se C8 do C24 alifatska karboksilna kiselina odnosno alifatske karboksilne kiseline koje se koriste u koraku (b) primjenjuju u rastaljenom stanju.
The pharmaceutical composition of claim 1, wherein the composition comprises 50-500 ug/mL of PRG4. 
Farmaceutski oblik za uporabu prema zahtjevu 1 ili 2, gdje farmaceutski oblik sadrži PRG4 u terapijski učinkovitoj koncentraciji od 50-500 ug/mL.
A process according to claim 6 or claim 8 wherein step (iii) or step (b) further comprises applying microwave energy to the solid material from step (ii) or (a). 
Postupak u skladu s bilo kojim od patentnih zahtjeva 7 do 10, pri čemu korak (111) ili korak (b) nadalje obuhvaćaju primjenu energije mikrovalova na čvrsti materijal 12 koraka (11) ili (a), gdje je frekvencija energije mikrovalova poželjno u rasponu od 2.45 GHz do 900 MHz.
e.g. 40-O-(2-hydroxyethyl)-rapamycin (herein also designated as “compound A”). 
40-O-(2-hidroksietil)-rapamicin, naznačen time, da se upotrebljava za obradu invazivnosti neuroendokrinog tumora pankreasa.
Salt according to paragraph 11, which is rosuvastatin 1-[(4-chlorophenyl)-phenyl-methyl]piperazinium salt which exhibits a powder x-ray diffraction pattern measured using CuKa-radiation having characteristic peak locations of 10.0, 16.7, 17.9 and 20.2 ± 0.2 degrees 2θ. Salt according to paragraph 13, which is rosuvastatin 1-[(4-chlorophenyl)-phenyl-methyl]piperazinium salt which exhibits a powder x-ray diffraction pattern measured using CuKa-radiation having characteristic peak locations of 10.0, 11.6, 16.7, 17.9, 20.2, 22.5 and 23.7 ± 0.2 degrees 2θ. 
Sol prema zahtjevu 5, naznačena time, da je to rosuvastatin-1-[(4-klorofenil)-fenil-metillpiperazin-sol koja prikazuje uzorak difrakcije praha X-zraka mjeren uporabom CuKa-radijacije, s mjestima karakterističnih vršnih vrijednosti na 10,0, 16,7, 17,9 1 20,2 + 0,2 stupnjeva 20, poželjno na 10,0, 11,6, 16,7, 17,9, 20,2, 22,5 i 23,7 +0,2 stupnjeva 20, i još bolje pokazuje uzorak difrakcije praha X-zraka uglavnom kako je prikazano na slici 1.
performing a nucleic acid amplification reaction, thereby producing the amplicon; and 
(b) izvođenje reakcije amplifikacije nukleinske kiseline, čime se dobiva amplikon; i
2 shows the solid-state carbon-13 CPMAS NMR spectrum for the crystalline monohydrate form of the dihydrogenphosphate salt of structural formula II. 
SL. 2 prikazuje kruti ugljik-13 CPMAS NMR spektar za kristalni monohidratni oblik dihidrogenfosfatne soli strukturne formule II.
wherein Aryl is phenyl optionally substituted with a substituent selected from the group consisting of halo, C1-4alkyl, -O-C1-4alkyl and -SO2-C1-4alkyl; 
pri čemu Aril je fenil po izboru supstituiran sa supstituentom odabranim iz skupine koju čine halo, C1-4alkil, -O-C1-4alkil i -SO2-C1-4alkil;
This was purified by flash silica gel column chromatography, eluting with 30% to 60% ethyl acetate in hexanes, to give a colorless oil. 
Ona je pročišćena pomoću flash kromatografije na koloni silika gela, eluiranjem sa 30% do 60% etil acetat u heksanima, da bi se dobilo bezbojno ulje.
The anti-CD20 antibody formulation for use according to Claim 1, wherein the sodium chloride is present in an amount of about 51mM. 
Formulacija protutijela an4-CD20 za uporabu prema zahtjevu 1, naznačena time, da je natrijev klorid prisutan u količini od 51 mM.
The process according to one of Claims 18 to 25, characterized in that the temperature in the first and/or the second insulator will be changed depending on each process step. 
Postupak prema jednom od Zahtjeva 18 do 25, naznačen time da se temperatura u prvom i/ili drugom izolatoru mijenja ovisno u koraku postupka koji je u tijeku.
A hybrid drive system for vehicle comprising at least an engine, characterized in that it further comprises a hybrid electric drive unit according to claim 1 . 
Hibridni pogonski sustav za vozilo koji se sastoji od barem jednog motora (1), naznačen time što nadalje sadrži hibridnu električnu pogonsku jedinicu prema bilo kojem od zahtjeva 1 do 11.
The immunogenic composition of any preceding claim wherein the at least two further bacterial saccharide conjugates comprise a S. pneumoniae capsular saccharide derived from a strain selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije S. pneumoniae kojeg se dobiva iz soja kojeg se bira iz skupine koju čine serotipovi 1, 2, 3, 4, 5, 6A, 6B, TF, 8, 9N, 9V, 10A, IA, 12F, 14, 15B, I7F, 18C, 19A, 19F, 20, 22F, 23F 133F.
The composition according to claim 3 wherein the antiviral agent is an anti-HCV agent. 
Sastav prema zahtjevu 13, naznačen time, da antivirusno sredstvo je jedno sljedeće anti-HCV-sredstvo.
each of R4 and R5, independently, is an optionally substituted aliphatic, aromatic, or heteroaromatic group, or R4 and R5, taken together with the intervening oxygen and boron atoms, form an optionally substituted 5- to 10-membered ring having 0-2 additional ring heteroatoms selected from N, O, or S; 
je nukleofugalna grupa ili izborno supstituirana alifatična, aromatična ili heteroaromatična grupa; i svaki od R4 i R5, nezavisno, je izborno supstituirana alifatična, aromatična ili heteroaromatična grupa, ili
The pharmaceutical composition according to claim 7, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, a L-nucleoside, and isatoribine and said interferon is a-interferon or pegylated interferon. 
Farmaceutska kompozicija prema patentnom zahtjevu 7, naznačena time što je navedeni nukleozidni analog izabran iz grupe koju čine ribavirin, viramidin, levovirin, L-nukleozid i izatoribin i navedeni interferon je a-interferon ili pegilirani interferon.
dry-milling the fat-extracted oat fraction by impact milling into oatmeal having such a particle size that at least 95% of the particles are between 1.0 and 3,000 µm calculated on the basis of the volume, 
(b) suho mljevenje frakcije zobi s ekstrahiranom masti putem impaktnog mljevenja u zobeno brašno s veličinom čestica takvom da barem 95% čestica bude između 1.0 13,000 um izračunato na temelju volumena,
A monoclonal antibody that binds to the polypeptide of claim 1 or 2; binds to human sclerostin with a dissociation constant of less than or equal to 1 x 10-9 M as determined by surface plasmon resonance; and increases at least one of bone formation, bone mineral density, bone mineral content, bone mass, bone quality and bone strength in a mammal. 
Monoklonsko protutijelo koje se veže za polipeptid iz patentnog zahtjeva 2, naznačen time, da se veže za humani sklerostin s disocijacijskom konstantom manjom ili jednakom od 1 x 10% M kako je izmjereno površinskom plazmonskom rezonancijom; te povećava barem jednu formaciju kosti, mineralnu gustoću kosti, mineralni sastav kosti, koštanu masu, kvalitetu kosti i jačinu kosti kod sisavca.
wherein any aforementioned 4-10 or 4-7 membered heterocycloalkyl group optionally comprises 1, 2, or 3 oxo substituents, wherein each oxo substituent that is present is substituted on a ring-forming carbon, nitrogen, or sulfur atom of the 4-10 or 4-7 membered heterocycloalkyl group. 
pri čemu bilo koja gore navedena 4-10 ili 4-7 -člana heterocikloalkil grupa izborno sadrži 1, 2 ili 3 okso supstituenta, pri čemu svaki okso supstituent koji je prisutan je supstituiran na atomu ugljika, azota ili sumpora koji formira prsten 4-10 ili 4-7 -člane heterocikloalkil grupe.
A kit comprising: a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, or a cell according to claim 6, in solution or in lyophilized form; and 
Kutije koja sadrži farmaceutski sastav koji se sastoji od peptida u skladu s bilo kojim zahtjevom 1 - 4, nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 5, stanice u skladu s patentnim zahtjevom 7 ili 8, ili aktiviranog citotoksičnog T-limfocita u skladu s patentnim zahtjevom 11, u otopini ili liofiliziranom obliku; i
transmitting higher layer control information indicating use of the transmission power value of the A-SRS based on the second accumulation value. The radio communication method according to claim 7, comprising: 
Postupak radio komunikacije sukladno zahtjevu 5, sadržeći primanje kontrolne informacije višeg sloja, naznačeno time da se navedeno upravljanje vrijednosti snage prijenosa A-SRS-a inicira nakon navedenog primanja kontrolne informacije višeg sloja.
The package according to claim 17, wherein said lactobacilli consist of the Lactobacillus brevis, Lactobacillus casei. Lactobacillus salivarius subs. salicinius and Lactobacillus gasseri species. 
Pakiranje u skladu s patentnim zahtjevom 17, naznačeno time što navedene laktobacile čine Lactobacillus brevis, Lactobacillus casei, Lactobacillus salivarius subsp. salicinius i Lactobacillus gasseri species.